Phase I Dose-Escalation Study of Tirapazamine Chemoembolization for Unresectable Early- and Intermediate-Stage Hepatocellular Carcinoma

医学 提拉帕扎明 肝细胞癌 不利影响 临床研究阶段 内科学 泌尿科 毒性 胃肠病学 生物化学 化学 细胞毒性 体外
作者
Chang-Hsien Liu,Cheng‐Ming Peng,Jen-I Hwang,Po‐Chin Liang,Pei‐Jer Chen,Nadine Abi‐Jaoudeh,Lung-Hui Giiang,Yu-Shen Tyan
出处
期刊:Journal of Vascular and Interventional Radiology [Elsevier]
卷期号:33 (8): 926-933.e1 被引量:5
标识
DOI:10.1016/j.jvir.2022.04.031
摘要

Purpose To investigate the safety of replacing doxorubicin with tirapazamine in conventional transarterial chemoembolization (TACE) in an Asian population with hepatocellular carcinoma (HCC), and to determine the optimal tirapazamine dose for phase II studies. Materials and Methods This was a phase I, 3 + 3 dose-escalation study for patients with unresectable early- and intermediate-stage HCC who received 5, 10, or 20 mg/m2 of intra-arterial (IA) tirapazamine followed by ethiodized oil/gelatin sponge-based embolization. Key eligibilities included HCCs no more than 10 cm in diameter, prior embolization allowed, Eastern Cooperative Oncology Group performance status of 0 or 1, Child-Pugh score of 5–7, and platelet count of ≥60,000 μL. Dose-limiting toxicity (DLT) was defined as any grade 3 nonhematological or grade 4 hematological toxicity, with the exception of transient elevation of aminotransferase levels after the procedure. Results Seventeen patients were enrolled, 59% of whom had progression from a prior HCC therapy and 35% of whom had progression or recurrence after TACE. All patients tolerated the tirapazamine TACE well without any DLT or serious adverse event. Using the modified Response Evaluation Criteria in Solid Tumors, the complete response (CR) rate was 47%, and the CR + partial response rate was 65%. The median duration of response was not reached. The median time to progression was 12.6 months (95% confidence interval, 5.1–not reached). The median overall survival was 29.3 months. The selected phase II dose was set at a fixed dose of 35 mg of IA tirapazamine. Conclusions IA tirapazamine with transarterial embolization was well tolerated and showed promising efficacy signals in intermediate-stage HCC, justifying pursuit of a phase II study.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
边渡有次子完成签到,获得积分10
1秒前
wanci应助老实的熊猫采纳,获得10
1秒前
默默的飞烟完成签到,获得积分10
2秒前
隐形鸣凤完成签到,获得积分10
5秒前
曲聋五完成签到 ,获得积分10
7秒前
嗯嗯嗯发布了新的文献求助10
7秒前
君子兰完成签到,获得积分10
8秒前
8秒前
我是老大应助lx33101128采纳,获得10
11秒前
小二郎应助白芷苏采纳,获得20
11秒前
13秒前
14秒前
Wt完成签到,获得积分20
14秒前
14秒前
打打应助强健的洋葱采纳,获得10
14秒前
14秒前
可爱的函函应助踏实以云采纳,获得10
15秒前
酷波er应助冬天配地瓜采纳,获得10
15秒前
岱山完成签到,获得积分10
15秒前
15秒前
16秒前
17秒前
Wt发布了新的文献求助10
17秒前
欣慰问柳发布了新的文献求助10
17秒前
JamesPei应助糊涂的涵雁采纳,获得10
18秒前
小杨完成签到,获得积分10
18秒前
21秒前
21秒前
搜集达人应助一二三四五采纳,获得10
25秒前
YvonneChem发布了新的文献求助10
25秒前
爱静静应助smu采纳,获得10
26秒前
嗯嗯嗯完成签到,获得积分10
26秒前
26秒前
Forever发布了新的文献求助10
26秒前
27秒前
27秒前
lujiajia发布了新的文献求助10
28秒前
28秒前
huadao发布了新的文献求助30
29秒前
ding应助Jayden采纳,获得10
31秒前
高分求助中
The late Devonian Standard Conodont Zonation 2000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
Very-high-order BVD Schemes Using β-variable THINC Method 870
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 800
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
Development of general formulas for bolted flanges, by E.O. Waters [and others] 600
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3256413
求助须知:如何正确求助?哪些是违规求助? 2898688
关于积分的说明 8301838
捐赠科研通 2567805
什么是DOI,文献DOI怎么找? 1394718
科研通“疑难数据库(出版商)”最低求助积分说明 652913
邀请新用户注册赠送积分活动 630562